Scientific advances in the treatment of chronic diseases are witnessing a significant boost since the last decade, which is attributed to the rising prevalence of diseases such as cancer. Cancer is one of the leading causes of mortality across the globe. According to the World Health Organization (WHO), cancer accounted for around 10 million deaths across the globe in 2020. As immunotherapy has been proven to provide lasting benefits for terminal patients, it is becoming the highly preferred therapy especially for patients with 3rd to 4th stage of cancer.
Immunotherapy clinically improves the body’s immune system to fight cancer cells. It is the most revolutionary therapy with significant potential for cancer treatment. Owing to the significant increase in the incidence rate of cancer, the immunotherapy drugs market is witnessing an exponential growth. According to the National Cancer Institute, the incidence rate of cancer was 442.4 per 100,000 between 2013 and 2017 and the annual number of new cases is expected to reach around 29.5 million by 2040. This is projected to augment the market during the forecast period.
Significant Investment by Key Pharmaceutical Giants to Develop Novel Immunotherapies to Propel Market Growth
- Rising focus of key companies to strengthen their pipeline drugs portfolio for cancer treatment to propel the immunotherapy drugs market size.
- Increased funding in R&D of novel immunotherapies to fights against cancer and other autoimmune disease will boost the global cancer immunotherapy market.
Improved Reimbursement Scenario for Cancer Treatment
- Increasing coverage for certain immunotherapy drugs by payors in emerging economies to contribute to the growth of the immunotherapy drugs market size.
- Smooth reimbursement procedures in developed countries for life-saving drugs is expected to propel the demand for immunotherapy drugs for cancer.
Clinical Benefits Associated with Monoclonal Antibodies to Boost Segment Growth
Based on product type, the immunotherapy drugs market is categorized into monoclonal antibodies, immune system modulators, adoptive cell therapies, and others. The monoclonal antibody segment is anticipated to dominate the immunotherapy drugs market share during the forecast period in terms of revenue, which is attributed to their efficacy and potency to disrupt the cancer cell activity. The improved distribution network of manufacturers and green signal by the USFDA and other regulatory authorities to approve numerous monoclonal antibodies across the globe are expected to augment the expansion of this segment in the coming years.
Efforts Being Made in Public and Private Healthcare Sectors Aiming to Increase R&D for Cancer Treatment to Augment Growth of Cancer Segment
On the basis of disease indication, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, and others. Cancer accounted for the highest market share in 2020 and is likely to lead the share during the forecast period. Rising prevalence of cancer due to improved diagnostic techniques for the disease and improved reimbursement coverage for cancer immunotherapies are the key factors for the estimated high growth of this segment.
Increased Funding and Rise in Research Activities in US and China to Boost Market in Respective Regions
Based on region, the immunotherapy drugs market is segmented into North America, Europe, APAC, Latin America, and Middle East & Africa. North America accounted for the highest revenue in 2020, attributed by the rising focus of key manufacturers to strengthen the drugs pipeline profile to stay ahead in the cutthroat competition in the US. Moreover, improved treatment algorithm for cancer and autoimmune diseases makes immunotherapy a preferred therapy type in the US and Canada is projected to boost the market growth in North America.
Europe is considered to hold the second position in the immunotherapy market in terms of value. The strategic presence of key companies such as Novartis, Roche, and AstraZeneca are expected to boost the revenue generation in Europe. However, APAC is expected to reflect relatively higher CAGR during the forecast period, which is attributable to the growing awareness of various novel therapies for the treatment of chronic diseases. Rising healthcare expenditure of the population, improved regulatory policies, and launches of novel immunotherapies are expected to boost the market growth of Latin America and the Middle East & Africa.
The immunotherapy drugs market is highly dynamic with various small-size, mid-size and big companies offering a wide range of immunotherapies. Emergence of local & regional players with enhanced R&D capabilities and their improved distribution network are the key factors responsible for making the market fragmented and competitive. Various biopharmaceutical giants such as Sanofi are adopting the mergers and acquisition strategy to expand their product portfolio and to expand the accessibility across the globe, which is expected to propel the market for such companies in coming years and make the market more fragmented.
Some prominent players in the immunotherapy market include Merck & Co., Inc., Abbvie, Samsung Bioepis, Novartis AG, GlaxoSmithKline, Eli Lilly & Company, Genentech, Inc., Johnson & Jonson Services, LLC., Bristol-Myers Squibb, Pfizer, Inc., AstraZeneca, Teva Pharmaceuticals, and Amgen.
Who Would Be Interested in This Research:
- Pharmaceutical & Biotech Companies
- Healthcare Facilities
- Public Health Organizations
- Raw Material Suppliers
- Regulatory Authorities
- Clinical Research Organizations
- Drug Discovery & Clinical Development Service Providers
- Academic Institutes & Research Institutes
- Consulting Companies
Pre-book this research or participate in the study to gain exclusive access to data-driven insights and trends in the immunotherapy drugs market.